In patients with chronic heart failure, iron deficiency, even in the absence of anaemia, can aggravate the underlying disease and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure recognize iron deficiency as a co-morbidity in chronic heart failure and recommend iron status screening in all newly diagnosed patients with chronic heart failure. Furthermore, the guidelines specifically recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron deficiency. However, in spite of these recommendations, iron deficiency remains often overlooked and undertreated. This may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physician. Here, we provide practical guidance complemented by a case study to assist and improve the timely diagnosis, treatment, and routine management of iron deficiency in patients with chronic heart failure.

Iron deficiency in chronic heart failure: case-based practical guidance / C.S.P. Lam, W. Doehner, J. Comin-Colet, C.S.P. Lam, W. Doehner, J. Comin-Colet, M.D. Cappellini, C. Camaschella, A.D. Francisco, A. Dignass, R. Kadir, I.C. Macdougall, D.R. Spahn, A.T. Taher, K.M. Musallam. - In: ESC HEART FAILURE. - ISSN 2055-5822. - 5:5(2018 Oct), pp. 764-771. [10.1002/ehf2.12333]

Iron deficiency in chronic heart failure: case-based practical guidance

M.D. Cappellini
Membro del Collaboration Group
;
2018

Abstract

In patients with chronic heart failure, iron deficiency, even in the absence of anaemia, can aggravate the underlying disease and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure recognize iron deficiency as a co-morbidity in chronic heart failure and recommend iron status screening in all newly diagnosed patients with chronic heart failure. Furthermore, the guidelines specifically recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron deficiency. However, in spite of these recommendations, iron deficiency remains often overlooked and undertreated. This may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physician. Here, we provide practical guidance complemented by a case study to assist and improve the timely diagnosis, treatment, and routine management of iron deficiency in patients with chronic heart failure.
Case study; Chronic heart failure; Ferric carboxymaltose; Iron deficiency; Practical guidance; Comorbidity; Global Health; Humans; Iron; Survival Rate; Anemia, Iron-Deficiency; Disease Management; Heart Failure; Practice Guidelines as Topic; Quality of Life; Cardiology and Cardiovascular Medicine
Settore MED/09 - Medicina Interna
ott-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
EHF2-5-764.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 403.03 kB
Formato Adobe PDF
403.03 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/614598
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 43
social impact